Afleveringen
-
Verve Ventures is a network and technology-driven venture capital firm headquartered in Switzerland. Founded in 2010, Verve Ventures has grown to more than 45 team members and has become one of the most active venture investors in Europe with over 140 technology and science-driven startups in its portfolio.
-
Cortex Discovery’s in silico drug discovery platform is based on its leading-edge AI technology which can predict molecule properties in all therapeutic fields. The accuracy of its predictions has been validated in the lab, and rivals that of experiments.
-
Zijn er afleveringen die ontbreken?
-
First Spark Ventures is a Deep Tech venture capital fund investing in breakthrough technologies that make the world healthier, safer, and more productive. First Spark Ventures invests in startups that have fundamental technological insights.We look for stellar teams,large accessible markets, and massive sustainable differentiation.
-
Oracle partners with leading independent software vendors (ISVs) that provide complementary application and technology solutions. Oracle program for ISVs offers a wealth of best practices, lessons learned, and results to share that have transformed—and continue to transform— cloud business. It encompasses Oracle experience migrating more than 60 SaaS-based applications to Oracle Cloud Infrastructure (OCI). These applications support core enterprise functions across eight industry verticals and more than 199,000 customers across the globe.
-
BioBox is a software company developing a hybrid Knowledge Graph and LLM system to create a new way for scientists to converse with data, without hallucinations. Fast moving teams in biotech are deploying the BioBox platform to hit R&D milestones in target identification and validation up to 5x faster.
-
Earlybird Venture Capital focuses on European technology companies. Founded in 1997, Earlybird identifies and backs exceptional early-stage companies on a pan-European basis and supports them through their growth and development phases – providing financial resources, strategic support, and access to an international network & capital markets. With EUR 2 billion under management across all fund streams, 9 IPOs, and 31 trade sales, Earlybird is one of Europe’s most established and active venture capital firms.
-
Prometheus Life Technologies is a space biology company out of the University of Zurich, specialized in producing organoids in microgravity. Our team is among the world’s most foremost experts in gravitational biology, and has already successfully flown two missions to the International Space Station to grow human tissue organoids, but we are just getting started on our journey to provide health from space for Earth, and to take biotech to new heights.
-
AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies.
-
Finishing her PhD in Advanced Therapies and Regenerative Medecine at King's College in UK right now, Sofia is on a mission to support visionaries and companies that develop disruptive solutions for humanity's most pressing challenges, from solving disease to sustainable longevity and environmental preservation. Artificial intelligence and synthetic biology are rapidly evolving, and the impact is tangible in all of our lives. This very intersection is where she believes we will find groundbreaking solutions for neuroscience, novel therapeutics, longevity and beyond.
Venture Associate in charge of the Neuroscience vertical at Next Sequence, she is working with founders that share that vision and are poised to reshape these frontiers. -
Beneficial Bio is a network of social enterprises run by biologists which aims to change the status quo for access to biological tools from scarcity to abundance, accelerating research, innovation and education for the bioeconomy. Beneficial Bio’s short term impact is accelerating and scaling local research. Our long term impact is increasing the agency of more people to shape biotechnology, particularly solving local problems without reliance on foreign priorities and developing resilient and autonomous supply chains for research and diagnostics.
-
After earning his Ph.D. in Biomaterials & Bioengineering from ETH Zurich, Alexandre played a pivotal role in establishing Switzerland's first cultivated meat production line, leading the development of innovative bioreactor designs, bioprocessing techniques, and bio-based materials for cultivating stem cells, muscle, and fat tissues.
Currently, Alexandre is actively involved with Next Sequence as a Venture Associate, where he supports TechBio startups in the Food & Agriculture sector.
-
NatureBound is on a mission to regenerate the biodiversity that underpins our food systems.
Combining the latest technology in remote sensing and AI with an open ecosystem of monitoring providers, our ML models leverage scalable biodiversity monitoring to predict agricultural outcomes. Integrating agricultural and biodiversity data across monitoring suppliers into our platform enables a swifter and more profitable transition to sustainable agriculture.
Making siloed biodiversity a thing of the past, NatureBound is building the first Biodiversity Observability Platform.
-
Zafrens exists at the confluence of engineering, biology, chemistry and informatics to study cells as comprehensively as possible. We map the molecular states of millions of cells at a time to their individual functional manifestations. In doing so we begin to understand the regulatory layers of the cell (how molecular state is converted to function), which, so far has remained challenging to study.
-
Alex Felman is a veteran of the family office community for almost a decade; working as managing director with his own family office, Felman Family Office, on the ground with local families in Brazil, China, Denmark and South Korea and remotely with other family offices around the globe.
He uses his expertise in Molecular Toxicology andBio-entrepreneurship(B.A from University of California -Berkeley, MBA from Copenhagen Business School) to advise them in biotechnology, healthcare, and other futuristic tech industries with the goal of maintaining long-term wealth through innovation.
He is personally involved with a number of early-stage companies having previously worked as a general partner of Venture Labs, an early stage venture capital/ incubator fund as well as a mentor, advisor, serial entrepreneur and director of numerous startups. Alex is an expert in helping companies with business plan creation, product development, operations, successful market launches, and fundraising.
- Laat meer zien